Editor's Choice – Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study

• Published in: European journal of vascular and endovascular surgery Vol. 69; no. 3; pp. 452 - 462
• Main Authors: Brodmann, Marianne, Gray, William A., Schneider, Peter A., Kurzmann-Guetl, Katharina, Schweiger, Leyla, Zeller, Thomas, Thieme, Marcus, Kilaru, Sashi, Bachinsky, William B., Feldman, Robert L., Holden, Andrew, Varcoe, Ramon L., Lansky, Alexandra J., Rosenfield, Kenneth
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.03.2025
• Subjects: Aged; Amputation, Surgical - statistics & numerical data; Angioplasty, Balloon - adverse effects; Angioplasty, Balloon - instrumentation; Balloon angioplasty; Cardiovascular Agents - administration & dosage; Cardiovascular Agents - adverse effects; Coated Materials, Biocompatible; Drug coated balloon; Female; Femoral Artery - diagnostic imaging; Femoral Artery - physiopathology; Femoropopliteal lesions; Humans; Limb Salvage; Male; Middle Aged; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Paclitaxel coated balloon; Peripheral arterial disease; Peripheral Arterial Disease - diagnostic imaging; Peripheral Arterial Disease - physiopathology; Peripheral Arterial Disease - therapy; Popliteal Artery - diagnostic imaging; Popliteal Artery - physiopathology; Prospective Studies; Single-Blind Method; Surgery; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Balloon angioplasty; Peripheral arterial disease; Drug coated balloon; Femoropopliteal lesions; Paclitaxel coated balloon

The aim of the TRANSCEND study was to compare the safety and efficacy of the next generation SurVeil PCB with the IN.PACT Admiral PCB in patients with femoropopliteal arterial disease. SurVeil is a lower dose PCB (2.0 μg/mm2vs. 3.5 μg/mm2 for IN.PACT Admiral) with a uniform microcrystalline coating...